{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T14:43:51Z","timestamp":1792075431157,"version":"4.4.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2022,9,21]],"date-time":"2022-09-21T00:00:00Z","timestamp":1663718400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,21]],"date-time":"2022-09-21T00:00:00Z","timestamp":1663718400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Major New Drugs Innovation and Development"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Triple-negative breast cancer (TNBC) is a heterogeneous subtype of breast cancer that displays highly aggressive with poor prognosis. Owing to the limited targets and drugs for TNBC clinical therapy, it is necessary to investigate the factors regulating cancer progression and develop novel therapies for cancer treatment. Ferroptosis, a nonapoptotic form of programmed cell death characterized by accumulation of iron-dependent peroxidation of phospholipids, is regulated by cellular metabolism, redox homeostasis, and various cancer-related signaling pathways. Recently, considerable progress has been made in demonstrating the critical role of lipid metabolism in regulating ferroptosis, indicating potential combinational therapeutic strategies for cancer treatment. In this study, by drug combination screen of lipid metabolism compounds with ferroptosis inducers in decreasing TNBC cell viability, we found potent synergy of the CB1 antagonist rimonabant with erastin\/(1\u2009S, 3\u2009R)-RSL3 (RSL3) in inhibiting TNBC cell growth both in vitro and in vivo via promoting the levels of lipid peroxides, malondialdehyde (MDA), 4-hydroxynonenal (4-HNE) and cytosolic reactive oxygen species (ROS) production, enhancing intracellular glutathione (GSH) depletion and inducing G1 cell cycle arrest. We identified that inhibition of CB1 promoted the effect of erastin\/RSL3 on inducing ferroptosis and enhanced their inhibitory effect on tumor growth. Using RNA-Seq, fatty acid analyses and functional assays, we found that CB1 regulated stearoyl-CoA desaturase 1 (SCD1)- and fatty acyl desaturase 2 (FADS2)-dependent fatty acid metabolism via phosphatidylinositol 3 kinase (PI3K)-AKT and mitogen-activated protein kinase (MAPK) signaling pathways to modulate ferroptosis sensitivity in TNBC cells. These data demonstrate that dual targeting of CB1 and ferroptosis could be a promising therapeutic strategy for TNBC.<\/jats:p>","DOI":"10.1038\/s41419-022-05242-5","type":"journal-article","created":{"date-parts":[[2022,9,21]],"date-time":"2022-09-21T04:03:26Z","timestamp":1663733006000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":79,"title":["Inhibition of cannabinoid receptor type 1 sensitizes triple-negative breast cancer cells to ferroptosis via regulating fatty acid metabolism"],"prefix":"10.1038","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1592-6554","authenticated-orcid":false,"given":"Pengyun","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiaohong","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiyang","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengjie","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoxin","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maoxiang","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3477-8243","authenticated-orcid":false,"given":"Yilong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0278-2531","authenticated-orcid":false,"given":"Zhibing","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,21]]},"reference":[{"key":"5242_CR1","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1016\/j.mayocp.2018.03.025","volume":"93","author":"CC O\u2019Sullivan","year":"2018","unstructured":"O\u2019Sullivan CC, Loprinzi CL, Haddad TC. Updates in the evaluation and management of breast cancer. Mayo Clin Proc. 2018;93:794\u2013807.","journal-title":"Mayo Clin Proc"},{"key":"5242_CR2","doi-asserted-by":"crossref","unstructured":"Lee KL, Kuo YC, Ho YS, Huang YH. Triple-negative breast cancer: current understanding and future therapeutic breakthrough targeting cancer stemness. Cancers. 2019;11:478\u201390.","DOI":"10.3390\/cancers11091334"},{"key":"5242_CR3","doi-asserted-by":"publisher","first-page":"2600","DOI":"10.1200\/JCO.2017.72.5960","volume":"35","author":"G Curigliano","year":"2017","unstructured":"Curigliano G. Maximizing the clinical benefit of anthracyclines in addition to taxanes in the adjuvant treatment of early breast cancer. J Clin Oncol. 2017;35:2600\u20133.","journal-title":"J Clin Oncol"},{"key":"5242_CR4","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1177\/1758834017711380","volume":"9","author":"K Oualla","year":"2017","unstructured":"Oualla K, El-Zawahry HM, Arun B, Reuben JM, Woodward WA, Gamal El-Din H, et al. Novel therapeutic strategies in the treatment of triple-negative breast cancer. Ther Adv Med Oncol. 2017;9:493\u2013511.","journal-title":"Ther Adv Med Oncol"},{"key":"5242_CR5","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.tcb.2015.10.014","volume":"26","author":"WS Yang","year":"2016","unstructured":"Yang WS, Stockwell BR. Ferroptosis: death by lipid peroxidation. Trends Cell Biol. 2016;26:165\u201376.","journal-title":"Trends Cell Biol"},{"key":"5242_CR6","doi-asserted-by":"publisher","unstructured":"Sui S, Xu S, Pang D. Emerging role of ferroptosis in breast cancer: New dawn for overcoming tumor progression. Pharmacol Ther. 2021. https:\/\/doi.org\/10.1016\/j.pharmthera.2021.107992.","DOI":"10.1016\/j.pharmthera.2021.107992"},{"key":"5242_CR7","doi-asserted-by":"crossref","unstructured":"Lin HY, Ho HW, Chang YH, Wei CJ, Chu PY. The evolving role of ferroptosis in breast cancer: translational implications present and future. Cancers. 2021;13:4576.","DOI":"10.3390\/cancers13184576"},{"key":"5242_CR8","doi-asserted-by":"publisher","first-page":"eaba8968","DOI":"10.1126\/sciadv.aba8968","volume":"6","author":"N Verma","year":"2020","unstructured":"Verma N, Vinik Y, Saroha A, Nair NU, Ruppin E, Mills G, et al. Synthetic lethal combination targeting BET uncovered intrinsic susceptibility of TNBC to ferroptosis. Sci Adv. 2020;6:eaba8968.","journal-title":"Sci Adv"},{"key":"5242_CR9","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/nchembio.2239","volume":"13","author":"S Doll","year":"2017","unstructured":"Doll S, Proneth B, Tyurina YY, Panzilius E, Kobayashi S, Ingold I, et al. ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition. Nat Chem Biol. 2017;13:91\u20138.","journal-title":"Nat Chem Biol"},{"key":"5242_CR10","doi-asserted-by":"crossref","unstructured":"Hasegawa M, Takahashi H, Rajabi H, Alam M, Suzuki Y, Yin L, et al. Functional interactions of the cystine\/glutamate antiporter, CD44v and MUC1-C oncoprotein in triple-negative breast cancer cells. Oncotarget. 2016;7:11756\u201369.","DOI":"10.18632\/oncotarget.7598"},{"key":"5242_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2016.208","volume":"7","author":"S Ma","year":"2016","unstructured":"Ma S, Henson ES, Chen Y, Gibson SB. Ferroptosis is induced following siramesine and lapatinib treatment of breast cancer cells. Cell Death Dis. 2016;7:e2307.","journal-title":"Cell Death Dis"},{"key":"5242_CR12","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.cmet.2019.11.010","volume":"31","author":"MT Snaebjornsson","year":"2020","unstructured":"Snaebjornsson MT, Janaki-Raman S, Schulze A. Greasing the wheels of the cancer machine: the role of lipid metabolism in cancer. Cell Metab. 2020;31:62\u201376.","journal-title":"Cell Metab"},{"key":"5242_CR13","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrclinonc.2016.60","volume":"14","author":"UE Martinez-Outschoorn","year":"2017","unstructured":"Martinez-Outschoorn UE, Peiris-Pages M, Pestell RG, Sotgia F, Lisanti MP. Cancer metabolism: a therapeutic perspective. Nat Rev Clin Oncol. 2017;14:11\u201331.","journal-title":"Nat Rev Clin Oncol"},{"key":"5242_CR14","doi-asserted-by":"publisher","first-page":"3006","DOI":"10.1172\/JCI127201","volume":"129","author":"Y Cao","year":"2019","unstructured":"Cao Y. Adipocyte and lipid metabolism in cancer drug resistance. J Clin Invest. 2019;129:3006\u201317.","journal-title":"J Clin Invest"},{"key":"5242_CR15","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/s41392-020-00216-5","volume":"5","author":"D Li","year":"2020","unstructured":"Li D, Li Y. The interaction between ferroptosis and lipid metabolism in cancer. Signal Transduct Tar. 2020;5:108.","journal-title":"Signal Transduct Tar"},{"key":"5242_CR16","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1038\/s41418-019-0418-2","volume":"26","author":"M Carbone","year":"2019","unstructured":"Carbone M, Melino G. Lipid metabolism offers anticancer treatment by regulating ferroptosis. Cell Death Differ. 2019;26:2516\u20139.","journal-title":"Cell Death Differ"},{"key":"5242_CR17","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s40880-018-0301-4","volume":"38","author":"C Cheng","year":"2018","unstructured":"Cheng C, Geng F, Cheng X, Guo D. Lipid metabolism reprogramming and its potential targets in cancer. Cancer Commun. 2018;38:27.","journal-title":"Cancer Commun"},{"key":"5242_CR18","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.plipres.2016.02.002","volume":"62","author":"FA Iannotti","year":"2016","unstructured":"Iannotti FA, Di Marzo V, Petrosino S. Endocannabinoids and endocannabinoid-related mediators: targets, metabolism and role in neurological disorders. Prog Lipid Res. 2016;62:107\u201328.","journal-title":"Prog Lipid Res"},{"key":"5242_CR19","doi-asserted-by":"crossref","unstructured":"Stasiulewicz A, Znajdek K, Grudzien M, Pawinski T, Sulkowska AJI. A Guide to targeting the endocannabinoid system in drug design. Int J Mol Sci. 2020;21:2778.","DOI":"10.3390\/ijms21082778"},{"key":"5242_CR20","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1158\/1535-7163.MCT-10-1100","volume":"10","author":"A Shrivastava","year":"2011","unstructured":"Shrivastava A, Kuzontkoski PM, Groopman JE, Prasad A. Cannabidiol induces programmed cell death in breast cancer cells by coordinating the cross-talk between apoptosis and autophagy. Mol Cancer Ther. 2011;10:1161\u201372.","journal-title":"Mol Cancer Ther"},{"key":"5242_CR21","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.tips.2013.03.003","volume":"34","author":"S Pisanti","year":"2013","unstructured":"Pisanti S, Picardi P, D\u2019Alessandro A, Laezza C, Bifulco M. The endocannabinoid signaling system in cancer. Trends Pharm Sci. 2013;34:273\u201382.","journal-title":"Trends Pharm Sci"},{"key":"5242_CR22","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","volume":"70","author":"T-C Chou","year":"2010","unstructured":"Chou T-C. Drug combination studies and their Synergy quantification using the Chou-Talalay method. Cancer Res. 2010;70:440.","journal-title":"Cancer Res"},{"key":"5242_CR23","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1146\/annurev-cancerbio-030518-055844","volume":"3","author":"SJ Dixon","year":"2019","unstructured":"Dixon SJ, Stockwell BR. The hallmarks of ferroptosis. Annu Rev Cancer Biol. 2019;3:35\u201354.","journal-title":"Annu Rev Cancer Biol"},{"key":"5242_CR24","first-page":"323","volume":"19","author":"Y Li","year":"2020","unstructured":"Li Y, Yan H, Xu X, Liu H, Wu C, Zhao L. Erastin\/sorafenib induces cisplatin-resistant non-small cell lung cancer cell ferroptosis through inhibition of the Nrf2\/xCT pathway. Oncol Lett. 2020;19:323\u201333.","journal-title":"Oncol Lett"},{"key":"5242_CR25","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13045-019-0720-y","volume":"12","author":"Y Mou","year":"2019","unstructured":"Mou Y, Wang J, Wu J, He D, Zhang C, Duan C, et al. Ferroptosis, a new form of cell death: opportunities and challenges in cancer. J Hematol Oncol. 2019;12:34.","journal-title":"J Hematol Oncol"},{"key":"5242_CR26","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.cell.2013.12.010","volume":"156","author":"WS Yang","year":"2014","unstructured":"Yang WS, SriRamaratnam R, Welsch ME, Shimada K, Skouta R, Viswanathan VS, et al. Regulation of ferroptotic cancer cell death by GPX4. Cell 2014;156:317\u201331.","journal-title":"Cell"},{"key":"5242_CR27","doi-asserted-by":"publisher","first-page":"32433","DOI":"10.1073\/pnas.2006828117","volume":"117","author":"J-Y Lee","year":"2020","unstructured":"Lee J-Y, Nam M, Son HY, Hyun K, Jang SY, Kim JW, et al. Polyunsaturated fatty acid biosynthesis pathway determines ferroptosis sensitivity in gastric cancer. Proc Natl Acad Sci USA. 2020;117:32433.","journal-title":"Proc Natl Acad Sci USA"},{"key":"5242_CR28","doi-asserted-by":"publisher","first-page":"108738","DOI":"10.1016\/j.celrep.2021.108738","volume":"34","author":"RSE Young","year":"2021","unstructured":"Young RSE, Bowman AP, Williams ED, Tousignant KD, Bidgood CL, Narreddula VR, et al. Apocryphal FADS2 activity promotes fatty acid diversification in cancer. Cell Rep. 2021;34:108738.","journal-title":"Cell Rep."},{"key":"5242_CR29","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.plipres.2009.12.002","volume":"49","author":"H Guillou","year":"2010","unstructured":"Guillou H, Zadravec D, Martin PG, Jacobsson A. The key roles of elongases and desaturases in mammalian fatty acid metabolism: Insights from transgenic mice. Prog Lipid Res. 2010;49:186\u201399.","journal-title":"Prog Lipid Res"},{"key":"5242_CR30","doi-asserted-by":"publisher","first-page":"108917","DOI":"10.1016\/j.cbi.2019.108917","volume":"316","author":"K Kikuchi","year":"2020","unstructured":"Kikuchi K, Tsukamoto H. Stearoyl-CoA desaturase and tumorigenesis. Chem Biol Interact. 2020;316:108917.","journal-title":"Chem Biol Interact"},{"key":"5242_CR31","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1038\/s41586-019-0904-1","volume":"566","author":"K Vriens","year":"2019","unstructured":"Vriens K, Christen S, Parik S, Broekaert D, Yoshinaga K, Talebi A, et al. Evidence for an alternative fatty acid desaturation pathway increasing cancer plasticity. Nature 2019;566:403\u20136.","journal-title":"Nature"},{"key":"5242_CR32","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/s41416-019-0650-z","volume":"122","author":"N Koundouros","year":"2020","unstructured":"Koundouros N, Poulogiannis G. Reprogramming of fatty acid metabolism in cancer. Br J Cancer. 2020;122:4\u201322.","journal-title":"Br J Cancer"},{"key":"5242_CR33","first-page":"3799","volume":"31","author":"S Sreevalsan","year":"2011","unstructured":"Sreevalsan S, Joseph S, Jutooru I, Chadalapaka G, Safe SH. Induction of apoptosis by cannabinoids in prostate and colon cancer cells is phosphatase dependent. Anticancer Res. 2011;31:3799.","journal-title":"Anticancer Res"},{"key":"5242_CR34","doi-asserted-by":"publisher","first-page":"2566","DOI":"10.1111\/bph.14331","volume":"175","author":"AI Fraguas-Sanchez","year":"2018","unstructured":"Fraguas-Sanchez AI, Martin-Sabroso C, Torres-Suarez AI. Insights into the effects of the endocannabinoid system in cancer: a review. Br J Pharm. 2018;175:2566\u201380.","journal-title":"Br J Pharm"},{"key":"5242_CR35","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1124\/mol.106.025601","volume":"70","author":"D Sarnataro","year":"2006","unstructured":"Sarnataro D, Pisanti S, Santoro A, Gazzerro P, Malfitano AM, Laezza C, et al. The cannabinoid CB1 receptor antagonist rimonabant (SR141716) inhibits human breast cancer cell proliferation through a lipid raft-mediated mechanism. Mol Pharm. 2006;70:1298\u2013306.","journal-title":"Mol Pharm"},{"key":"5242_CR36","doi-asserted-by":"publisher","first-page":"949","DOI":"10.3389\/fphar.2017.00949","volume":"8","author":"D Fiore","year":"2017","unstructured":"Fiore D, Ramesh P, Proto MC, Piscopo C, Franceschelli S, Anzelmo S, et al. Rimonabant kills colon cancer stem cells without inducing toxicity in normal colon organoids. Front Pharm. 2017;8:949.","journal-title":"Front Pharm"},{"key":"5242_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-11688-x","volume":"7","author":"MC Proto","year":"2017","unstructured":"Proto MC, Fiore D, Piscopo C, Franceschelli S, Bizzarro V, Laezza C, et al. Inhibition of Wnt\/beta-Catenin pathway and Histone acetyltransferase activity by Rimonabant: a therapeutic target for colon cancer. Sci Rep. 2017;7:11678.","journal-title":"Sci Rep."},{"key":"5242_CR38","first-page":"365","volume":"65","author":"AMA Malfitano","year":"2012","unstructured":"Malfitano AMA. The CB1 receptor antagonist rimonabant controls cell viability and ascitic tumour. Pharm Rev. 2012;65:365\u201371.","journal-title":"Pharm Rev"},{"key":"5242_CR39","doi-asserted-by":"publisher","first-page":"107477","DOI":"10.1016\/j.pharmthera.2020.107477","volume":"208","author":"R Cinar","year":"2020","unstructured":"Cinar R, Iyer MR, Kunos G. The therapeutic potential of second and third generation CB1R antagonists. Pharm Therapeut. 2020;208:107477.","journal-title":"Pharm Therapeut"},{"key":"5242_CR40","doi-asserted-by":"publisher","first-page":"5355","DOI":"10.1158\/0008-5472.CAN-19-0369","volume":"79","author":"L Tesfay","year":"2019","unstructured":"Tesfay L, Paul BT, Konstorum A, Deng Z, Cox AO, Lee J, et al. Stearoyl-CoA desaturase 1 protects ovarian cancer cells from ferroptotic cell death. Cancer Res. 2019;79:5355\u201366.","journal-title":"Cancer Res"},{"key":"5242_CR41","doi-asserted-by":"publisher","first-page":"31189","DOI":"10.1073\/pnas.2017152117","volume":"117","author":"J Yi","year":"2020","unstructured":"Yi J, Zhu J, Wu J, Thompson CB, Jiang X. Oncogenic activation of PI3K-AKT-mTOR signaling suppresses ferroptosis via SREBP-mediated lipogenesis. Proc Natl Acad Sci USA. 2020;117:31189\u201397.","journal-title":"Proc Natl Acad Sci USA"},{"key":"5242_CR42","doi-asserted-by":"publisher","first-page":"3293","DOI":"10.7150\/thno.19988","volume":"7","author":"Y Jiang","year":"2017","unstructured":"Jiang Y, Mao C, Yang R, Yan B, Shi Y, Liu X, et al. EGLN1\/c-Myc induced lymphoid-specific Helicase inhibits ferroptosis through lipid metabolic gene expression changes. Theranostics 2017;7:3293\u2013305.","journal-title":"Theranostics"},{"key":"5242_CR43","doi-asserted-by":"crossref","unstructured":"Stockwell BR. Emerging mechanisms and disease relevance of ferroptosis. Trends Cell Biol. 2020;30:478-490.","DOI":"10.1016\/j.tcb.2020.02.009"},{"key":"5242_CR44","doi-asserted-by":"crossref","unstructured":"Salaroglio IC, Mungo E, Gazzano E, Kopecka J, Riganti C. ERK is a pivotal player of chemo-immune-resistance in cancer. Int J Mol Sci. 2019;20:2505.","DOI":"10.3390\/ijms20102505"},{"key":"5242_CR45","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.semcancer.2019.06.002","volume":"59","author":"S Revathidevi","year":"2019","unstructured":"Revathidevi S, Munirajan AK. Akt in cancer: mediator and more. Semin Cancer Biol. 2019;59:80\u201391.","journal-title":"Semin Cancer Biol"},{"key":"5242_CR46","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.ejmech.2016.01.012","volume":"109","author":"V Asati","year":"2016","unstructured":"Asati V, Mahapatra DK, Bharti SK. PI3K\/Akt\/mTOR and Ras\/Raf\/MEK\/ERK signaling pathways inhibitors as anticancer agents: structural and pharmacological perspectives. Eur J Med Chem. 2016;109:314\u201341.","journal-title":"Eur J Med Chem"},{"key":"5242_CR47","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1016\/j.ccell.2018.03.017","volume":"33","author":"J Tsoi","year":"2018","unstructured":"Tsoi J, Robert L, Paraiso K, Galvan C, Sheu KM, Lay J, et al. Multi-stage differentiation defines melanoma subtypes with differential vulnerability to drug-induced iron-dependent oxidative stress. Cancer Cell. 2018;33:890\u2013904. e5","journal-title":"Cancer Cell"},{"key":"5242_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s13402-019-00489-1","volume":"43","author":"D Cruceriu","year":"2020","unstructured":"Cruceriu D, Baldasici O, Balacescu O, Berindan-Neagoe I. The dual role of tumor necrosis factor-alpha (TNF-\u03b1) in breast cancer: molecular insights and therapeutic approaches. Cell Oncol. 2020;43:1\u201318.","journal-title":"Cell Oncol"},{"key":"5242_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-27948-4","volume":"13","author":"J Wu","year":"2022","unstructured":"Wu J, Feng Z, Chen L, Li Y, Bian H, Geng J, et al. TNF antagonist sensitizes synovial fibroblasts to ferroptotic cell death in collagen-induced arthritis mouse models. Nat Commun. 2022;13:676.","journal-title":"Nat Commun"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-022-05242-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-022-05242-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-022-05242-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,21]],"date-time":"2022-09-21T05:23:14Z","timestamp":1663737794000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-022-05242-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,21]]},"references-count":49,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2022,9]]}},"alternative-id":["5242"],"URL":"https:\/\/doi.org\/10.1038\/s41419-022-05242-5","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,21]]},"assertion":[{"value":"30 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All animal studies were performed strictly in accordance with the Animal Care Guidelines approved by the Institutional Animal Care Committee of Beijing Institute of Biotechnology.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"808"}}